France
Nova In Silico is a French startup that specializes in providing its unique jinkō clinical trials simulation platform to biotech and pharma companies, academic research centers, and not-for-profit organizations. The platform aims to de-risk and accelerate the R&D of new therapies, ultimately benefiting patients by optimizing drug regimens and identifying best responders.
The company, founded in 2010, operates within the Biotechnology and Health Care industries, leveraging modeling and simulation to explore research outcomes that may not be feasible with traditional trials. This innovative approach allows for the prediction of trial outcomes before advancing to real-world clinical trials and designing studies that are more likely to succeed.
Nova In Silico recently secured a €2.50M Series A investment on 16 February 2021, with Sanofi as the lead investor. This investment signifies a strong show of confidence in the potential of jinkō and the value it brings to the biotech and pharma sectors.
